Reuters: US FDA staff seeks input on Amgen clot drug risks

[chris]

US FDA staff seeks input on Amgen clot drug risks
      

WASHINGTON (Reuters) - U.S. drug reviewers will ask an advisory panel if an experimental Amgen Inc medicine for a rare blood disorder may carry a risk of clotting, cancer or other problems, documents released on Monday said.
<p>You are not allowed to view links. Register or Login</p><div class="feedflare">
You are not allowed to view links. Register or Login You are not allowed to view links. Register or Login You are not allowed to view links. Register or Login
</div><img src="You are not allowed to view links. Register or Login" height="1" width="1"/>
      

You are not allowed to view links. Register or Login